Emergency Department, GHU APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.
GRC-14 BIOSFAST, CIMI, UMR 1135, Sorbonne Université, Paris, France.
Crit Care. 2024 Oct 27;28(1):346. doi: 10.1186/s13054-024-05141-5.
Timely recognition of sepsis in emergency department (ED) is challenging. We evaluated the impact of implementing the biomarker monocyte distribution width (MDW) at bedside, on the time to anti-infective administration.
We conducted a before-and-after cohort study in the ED of an academic hospital in Paris, to compare sepsis patients care and outcomes, before and after the implementation of point of care (POC) MDW measurement in the ED. During post-implementation period (period-2), MDW was measured with complete blood count by ED nurses with results given in 2 min: if above 21.5 units, ED physicians were asked to consider sepsis and to start an anti-infectious as soon as possible. Primary endpoint was time to anti-infectious administration (TTA) from ED arrival, and secondary endpoints were TTA from sepsis onset (TTAS), length of stay, mortality, and hospitalization rates.
In total, 255 patients (period-1) and 180 patients (period-2) with sepsis were included. The TTA was 5.4 h (3.5-7.7) period-1 and 4.9 h (IQR 2.5-7.1) in period-2 (p = 0.06). MDW implementation significantly reduced the median TTAS from to 3.7 h (IQR 1.5-5.8) in period-1, to 2.2 h (IQR 0.5-4.5) in period-2 (p < 0.001). Mortality rates remained similar between the two periods (18% vs. 16% respectively, p = 0.4), as did hospitalization rates (93% vs. 91%, p = 0.4) and ED length of stay (7.2 h (5.3-9.8) vs 7.0 (5.4-9.4), p = 0.7).
Implementing POC MDW measurement in the ED protocols enhances the timeliness of anti-infective administration from sepsis onset, meeting current sepsis management guidelines.
在急诊科(ED)及时识别脓毒症具有挑战性。我们评估了在床边实施生物标志物单核细胞分布宽度(MDW)对开始抗感染治疗时间的影响。
我们在巴黎一家学术医院的 ED 进行了一项前后队列研究,比较了实施 ED 床边即时检测(POC)MDW 测量前后脓毒症患者的治疗和结局。在实施后期间(期 2),ED 护士用全血细胞计数测量 MDW,结果在 2 分钟内给出:如果高于 21.5 个单位,ED 医生被要求考虑脓毒症,并尽快开始抗感染治疗。主要终点是从 ED 到达开始抗感染治疗的时间(TTA),次要终点是从脓毒症发作开始的 TTA(TTAS)、住院时间、死亡率和住院率。
共有 255 例(期 1)和 180 例(期 2)脓毒症患者纳入研究。TTA 为 5.4 h(3.5-7.7)期 1 和 4.9 h(IQR 2.5-7.1)期 2(p=0.06)。MDW 的实施显著缩短了 TTAS 的中位数,从期 1 的 3.7 h(IQR 1.5-5.8)降至期 2 的 2.2 h(IQR 0.5-4.5)(p<0.001)。两个时期的死亡率相似(分别为 18%和 16%,p=0.4),住院率(分别为 93%和 91%,p=0.4)和 ED 住院时间(7.2 h(5.3-9.8)与 7.0 h(5.4-9.4),p=0.7)也相似。
在 ED 方案中实施 POC MDW 测量可提高从脓毒症发作开始抗感染治疗的及时性,符合当前脓毒症管理指南。